Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results
BOCA RATON, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and 12 months ended December 31, 2023.
- Revenues for the fourth quarter of 2023 were $12.6 million, compared with $13.1 million for the fourth quarter of 2022.
- Cost of sales was $4.7 million for the fourth quarter of 2023, compared with $4.8 million for the prior-year quarter.
- General and administrative expense was $1.0 million for the fourth quarter of 2023, compared with $1.4 million for the fourth quarter of 2022.
- Adjusted EBITDA for the fourth quarter of 2023 was $5.7 million, compared with $4.3 million for the fourth quarter of 2022.